Sirtex Medical jumps on surging sales, profits for fiscal 2016
By Sarah Faulkner Shares in Sirtex Medical (ASX:SRX) closed up nearly 12% today after the Australian medical device company posted huge boosts to both the bottom and top lines. Sydney-based Sirtex Medical makes targeted liver cancer therapies using resin microspheres called SIR-sphere Y-90. Sirtex said profits were $40.8 million (A$53.6 million), or 70¢ (A92.2¢) per share, on sales of $177.2 million (A$232.5 million) for the fiscal year ended June 30. That represents profit growth of 32.8% compared with fiscal 2015, on sales growth of 32.0%. “This record profit result once again highlights the continued execution of our strategies that seek to expand our global footprint, build clinician awareness and referrals, and increase reimbursement coverage for patients suffering from liver cancer,” Sirtex CEO Gilman Wong said in prepared remarks. “Our core SIR-Spheres Y-90 resin microspheres business represents a long term growth opportunity for Sirtex, given our FY16 dose sales imply we have only penetrated approximately 2% of our annual addressable market opportunity, globally.” Sirtex said it expects sales to grow at a double-digit clip during fiscal 2017. The jump confirms Sirtex’s preliminary results issued in July, when the company 1st reported the higher-than-expected sales and saw share prices climb 6.5%, the largest rise in more than 8 months. The news pushed SRX shares up 11.97% to a $26.51 (A$34.80) close today on ...
Publication date: Available online 17 July 2018Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Duarte de Melo-Diogo, Rita Lima-Sousa, Cátia G. Alves, Elisabete C. Costa, Ricardo O. Louro, Ilídio J. CorreiaAbstractGraphene family nanomaterials’ (GFN) ability to interact with near-infrared light has propelled their application in cancer photothermal therapy. Furthermore, the graphitic lattice of GFN can adsorb different types of molecules, which has motivated their use in cancer drug delivery. However, the direct application of GFN in cancer therapy is severely hindered by their poor colloidal st...
This study identified a previously unrecognized regulatory axis between AHR and polyamine metabolism and discovered clofazimine as an inhibitor of AHR and a potentially clinically-relevant anti-multiple myeloma agent.RNA-seq: human multiple myeloma MM1S and human normal fibroblasts WI38 cells -/+ CLF 2-4uM for 24hrs; -/+ shAHR
(Wiley) Previous research has shown that cannabinoids can help lessen side effects of anti-cancer therapies. Now a new British Journal of Pharmacology review has examined their potential for the direct treatment of cancer.
SummaryMicrotubule as an important target in the cancer therapy was used to design novel tubulin polymerization inhibitors. Sulfanilamide-1,2,3-triazole hybrids were designed by a molecular hybridization strategy and their antiproliferative activity against three selected cancer cell lines (BGC-823, MGC-803 and SGC-7901) were evaluated. All sulfanilamide-1,2,3-triazole hybrids displayed potent inhibitory activity against all cell lines. In particular, compound10b showed the most excellent inhibitory effect against MGC-803 cells, with an IC50 value of 0.4 μM. Cellular mechanism studies elucidated that10b induced apoptosi...
Treatment costs for the immunotherapy can run to more than $1 million. Some state Medicaid programs aren't paying for the treatment, and Medicare's complicated payment rates have hospitals worried.(Image credit: Fanatic Studio/Collection Mix: Subjects RF/Getty Images)
Conclusion: Our results indicate that SirT1 regulates apoptosis and radiation sensitization in lung cancer cell lines A549 and H460 via the SirT1/NF- κB/Smac pathway.Cell Physiol Biochem 2018;48:304 –316
Xingming Deng, Zhuofei Li, Guan Li, Bei Li, Xinhan Jin, Guoqing Lyu
There have been significant and continued improvements in the treatment for and survival from childhood cancer over the past few decades. Based on Australian and overseas statistics, the 5 year survival rates have improved to approximately 80% and the majority of these children will go on to become long term survivors (Baade et al., 2010; Gatta et al., 2009; Miller et al., 2016; Ries et al., 2008). Accompanying this increased survival, long-term physical and psychological consequences of cancer therapy are becoming more apparent.
Conclusion: Molecular mechanism and clinical efficacy of some of the emerging molecular targets for cancer chemotherapy have been briefly reviewed in the present article.
Cardiorenal complications of immune checkpoint inhibitors, Published online: 16 July 2018; doi:10.1038/s41581-018-0035-1Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy; however, these agents can induce immune-related adverse events (irAEs) in off-target organs. This Review describes the mechanism of action of ICI therapies and how these agents induce irAEs in the kidney and heart.